{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:40:40Z","timestamp":1765280440388,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open access funding provided by Tokyo Medical University."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Patients with chronic kidney disease (CKD) sometimes experience gastrointestinal symptoms, such as nausea and vomiting. In addition, hypertension and CKD are closely linked, and sustained hypertension in children is associated with the progression of CKD, leading to early cardiomyopathy and premature atherosclerosis. These symptoms substantially affect the quality of daily life of CKD patients, and particularly in children with CKD, they may cause growth retardation. Therefore, establishing effective management methods to alleviate these symptoms is very important. Here, we report a case of a male patient who was born at 34\u00a0weeks of gestation weighing 1400\u00a0g. At birth, abdominal ultrasonography displayed left multicystic dysplastic kidney. From 6\u00a0months after birth, he was frequently hospitalized owing to refractory periodic vomiting. At 9 months old, he was diagnosed as having stage 3a CKD, and at 20 months old, he presented with stage 2 high blood pressure. In Japan, the uremic toxin adsorbent AST-120 and angiotensin-converting enzyme inhibitor-I (ACE-I) are not strongly recommended for CKD patients. However, after the patient underwent combination therapy of AST-120 and ACE-I, his frequent hospitalizations for refractory periodic vomiting ceased, and his blood pressure decreased. These results indicate that AST-120 and ACE-I are effective for refractory periodic vomiting and hypertension associated with CKD. The patient\u2019s height, weight, and mental development are catching up smoothly. The cause of the patient\u2019s refractory periodic vomiting remains unclear. However, his impaired kidney function owing to congenital anomalies of the kidney and urinary tract may have caused the refractory periodic vomiting and dehydration. The production of uremic toxins in CKD patients is thought to lead to the secretion of proinflammatory cytokines into the circulation. However, our patient had low serum levels of proinflammatory cytokines, and his serum levels of the chemokines CX3CL1 and CCL2 decreased with age, together with improvement in his clinical course. Therefore, some specific chemokines might be diagnostic and\/or prognostic biomarkers of CKD.<\/jats:p>","DOI":"10.1007\/s13730-024-00905-y","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:03:22Z","timestamp":1720706602000},"page":"103-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of chronic kidney disease with refractory periodic vomiting and hypertension in a pediatric patient"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-1276","authenticated-orcid":false,"given":"Yasuyo","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaku","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"3","key":"905_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41581-021-00518-z","volume":"18","author":"K Kalantar-Zadeh","year":"2022","unstructured":"Kalantar-Zadeh K, Lockwood MB, Rhee CM, Tantisattamo E, Andreoli S, Balducci A, Laffin P, Harris T, Knight R, Kumaraswami L, Liakopoulos V, Lui SF, Kumar S, Ng M, Saadi G, Ulasi I, Tong A, Li PK. Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat Rev Nephrol. 2022;18(3):185\u201398.","journal-title":"Nat Rev Nephrol"},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJNRD.S41339","volume":"7","author":"G Schulman","year":"2014","unstructured":"Schulman G, Vanholder R, Niwa T. AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:49\u201356.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"905_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.ackd.2011.03.003","volume":"18","author":"RG VanDeVoorde","year":"2011","unstructured":"VanDeVoorde RG, Mitsnefes MM. Hypertension and CKD. Adv Chronic Kidney Dis. 2011;18(5):355\u201361.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"905_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"905_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/ped.13100","volume":"58","author":"R Nagao","year":"2016","unstructured":"Nagao R, Suzuki S, Kawashima H, Nozu K, Iijima K. Acute kidney injury in type 3 Bartter syndrome: angiotensin-converting enzyme inhibitors as a cause. Pediatr Int. 2016;58(12):1373\u20134.","journal-title":"Pediatr Int"},{"key":"905_CR6","unstructured":"Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2023."},{"issue":"71","key":"905_CR7","first-page":"e13","volume":"2018","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension. 2017;2018(71):e13\u2013115.","journal-title":"Hypertension"},{"issue":"Pt 3","key":"905_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.semcancer.2022.02.007","volume":"86","author":"SN Jia","year":"2022","unstructured":"Jia SN, Han YB, Yang R, Yang ZC. Chemokines in colon cancer progression. Semin Cancer Biol. 2022;86(Pt 3):400\u20137.","journal-title":"Semin Cancer Biol"},{"key":"905_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/278715","author":"AC Sim\u00f5es Silva","year":"2014","unstructured":"Sim\u00f5es Silva AC, Pereira AB, Teixeira MM, Teixeira AL. Chemokines as potential markers in pediatric renal diseases. Dis Markers. 2014. https:\/\/doi.org\/10.1155\/2014\/278715.","journal-title":"Dis Markers"},{"issue":"14","key":"905_CR10","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1111\/jcmm.16707","volume":"25","author":"Q Gong","year":"2021","unstructured":"Gong Q, Jiang Y, Pan X, You Y. Fractalkine aggravates LPS-induced macrophage activation and acute kidney injury via Wnt\/\u03b2-catenin signalling pathway. J Cell Mol Med. 2021;25(14):6963\u201375.","journal-title":"J Cell Mol Med"},{"key":"905_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.664202","volume":"12","author":"S Cormican","year":"2021","unstructured":"Cormican S, Griffin MD. Fractalkine (CX3CL1) and its receptor CX3CR1: a promising therapeutic target in chronic kidney disease? Front Immunol. 2021;12: 664202.","journal-title":"Front Immunol"},{"issue":"2","key":"905_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/path.5132","volume":"246","author":"C Gonz\u00e1lez-Guerrero","year":"2018","unstructured":"Gonz\u00e1lez-Guerrero C, Morgado-Pascual JL, Cannata-Ortiz P, Ramos-Barron MA, G\u00f3mez-Alamillo C, Arias M, Mezzano S, Egido J, Ruiz-Ortega M, Ortiz A, Ramos AM. CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. J Pathol. 2018;246(2):191\u2013204.","journal-title":"J Pathol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00905-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-024-00905-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00905-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:36:31Z","timestamp":1738380991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-024-00905-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s13730-024-00905-y","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest in association with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethics approval was not required for our case publication. We obtained written informed consent from the patient\u2019s parents to publish this case report. Written permission was also obtained from the patient\u2019s parents for the appearance of the patient\u2019s data in print, online, and licensed versions of the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}